10-K Decoder · All companies

Axsome Therapeutics, Inc.

AXSM · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$638M$386M+65.5%
Operating income−$167M−$281M+40.6%
Net income−$183M−$287M+36.2%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026

$Q3 2026Year earlierChange
Revenue$260M$171M+51.9%
Operating income−$11.1M−$46.1M+75.9%
Net income−$12.9M−$47.2M+72.7%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Axsome's revenue in FY2025?
$638M in FY2025 (Fiscal year ended Dec 31, 2025), +65.5% vs $386M a year earlier, per its 10-K filed Feb 2026.
Was Axsome profitable in FY2025?
No: net income was −$183M and operating income −$167M in FY2025.
What was Axsome's revenue in Q3 2026?
$260M (+51.9% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.